Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bioventus Inc
Depreciation & Amortization
Bioventus Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Depreciation & Amortization
$47m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Depreciation & Amortization
$112.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Depreciation & Amortization
$200.7m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
27%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Depreciation & Amortization
$237.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
20%
|
CAGR 10-Years
29%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Depreciation & Amortization
$70.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Depreciation & Amortization
$123.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Depreciation & Amortization?
Depreciation & Amortization
47m
USD
Based on the financial report for Dec 31, 2025, Bioventus Inc's Depreciation & Amortization amounts to 47m USD.
What is Bioventus Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
10%
Over the last year, the Depreciation & Amortization growth was -5%. The average annual Depreciation & Amortization growth rates for Bioventus Inc have been -11% over the past three years , 10% over the past five years .
